In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And modes of drug delivery are becoming increasingly complex.
Read More
The Indianapolis-based medical school ranked 29th in the country for landing funding from the National Institutes of Health.
Read More
During the last nine years, the cumulative amount of AI investments across the pharma and biotech sectors has increased by almost thirtyfold, to $24.6 billion as of last December.
Read More
The pharmaceutical company has launched 20 drugs in the past decade to treat diseases from arthritis and psoriasis to diabetes and cancer. In recent months, Lilly has overtaken every competitor to become the most valuable drugmaker in the world.
Read More
Kristin Sherman leads startup Kovina Therapeutics, which is still in the early stages of developing ways to stop human papillomavirus infections before cancer develops and to treat HPV cancers after detection.
Family members, a determined coroner and state researchers are behind a renewed effort to identify all of the unknown dead whose remains are among some 10,000 bones and fragments unearthed on Herbert Baumeister’s suburban Indianapolis property.
Kosali Simon, an Indiana University and Regenstrief Institute researcher, will study the treatment and outcomes of patients with Alzheimer’s and related dementias.
After 10 long years, the company that has developed a collagen biomaterial to help heal tissue is readying itself for its next big steps: regulatory approval and commercial launch.
Sen. Todd Young visited the 16 Tech innovation district Monday to underscore the work of a young federal agency that wants to shake up the conventional model of funding biomedical research.
The Joint Center of Excellence for Point of Care Precision Medicine aims to develop better personalized care for patients with diabetes, cancer, Alzheimer’s disease and pediatric rare disease.
Lilly is moving about 200 scientists and researchers who had worked in nearby Cambridge, Massachusetts, to the new center, and plans to add about 300 employees.
The Eli Lilly and Co. and Purdue University Research Alliance Center involves more than 50 researchers and 65 graduate students.
State and corporate leaders believe a tech park taking shape on the western edge of downtown could be a launchpad for health sciences innovation and commercialization as part of the state’s ambitious economic development portfolio.
The study followed a group of testicular cancer survivors for an average of 14 years, revealing that 78% experience significant difficulties in everyday listening situations.
James Lin, a biomedical researcher who has focused on new innovations for tissue engineering and regenerative medicine, will start his new job in Indianapolis on Aug. 26.
The goal is to ensure that new tests for cancer, heart disease, COVID-19, genetic conditions and many other illnesses are safe, accurate and reliable.
Indianapolis-based NICO recently wrapped up a large clinical trial that tested the company’s minimally invasive tools and technology for brain surgery in patients with hemorrhagic stroke. Now it faces a major decision.
The gift, announced Tuesday morning, is from local philanthropist Julie Wood, in honor of her late husband, Tom Wood, a prominent car dealer who died of lung cancer in 2010 at age 78.
The U.S. Food and Drug Administration designated psilocybin as a “breakthrough therapy” for treatment-resistant depression in 2018 and for major depressive disorder in 2019.
The live-work-play campus has been picked to join a new national network designed to connect researchers, entrepreneurs and investors to accelerate the development of health care products and services and speed up health care innovations.
The research published by the IU Richard M. Fairbanks School of Public Health found that one in five Indiana residents with mental illness do not receive the treatment they need.
A number of studies have found that people receiving vaccinations for flu and several other infectious diseases appear less likely than the unvaccinated to develop dementia, although scientists aren’t sure why.
Researcher Terry Loghmani and two colleagues have developed a medical device they say can help physical therapists monitor the level of pressure they apply to the soft tissue of patients seeking greater mobility and pain relief.
People who endured even mild cases of COVID-19 are at heightened risk two years later for lung problems, fatigue, diabetes and certain other health problems typical of long COVID, according to a new study that casts fresh light on the virus’s true toll.
